Eisai Co., Ltd. has announced plans to present significant findings from its Alzheimer's disease research, including data on its anti-amyloid beta (Aβ) protofibril antibody, lecanemab, at the Alzheimer's Association International Conference 2026 (AAIC) in London. The company will showcase 52 abstracts across its Alzheimer's disease portfolio, highlighting advancements in treatment and intervention strategies.
The presentations will include a Developing Topics Session and a Featured Research Session on lecanemab, featuring multiple oral presentations and posters. Eisai will also hold a symposium on early intervention in Alzheimer's disease, emphasizing the importance of timely treatment.
A key focus of the Developing Topics Session will be the subcutaneous formulation of lecanemab, exploring clinical evidence and real-world patient experiences. The Featured Research Session will present data from the LEADER study, evaluating real-world use of lecanemab in diverse U.S. clinical settings three years post-approval. This includes findings on maintenance dosing with intravenous treatment and subcutaneous administration at home.
Additional presentations will cover the Phase 3 AHEAD 3-45 study in preclinical Alzheimer's disease, providing updates on participant retention and engagement. There will also be discussions on a Phase 2 trial of etalanetug, an anti-MTBR tau antibody, in combination with lecanemab, examining its effects on tau pathology.
Lynn D. Kramer, M.D., FAAN, Chief Clinical Officer of Deep Human Biology Learning at Eisai, highlighted the company's commitment to advancing Alzheimer's care through a comprehensive data set spanning the disease continuum and multiple therapeutic targets.
Other sessions will delve into various aspects of lecanemab's clinical application, such as sex-based outcomes, racial and ethnic differences in biomarkers, and the economic impact of delayed Alzheimer's progression. The conference will also feature presentations on etalanetug, exploring its potential as a disease-modifying therapy for tauopathies.
Eisai's collaboration with Biogen and BioArctic has been pivotal in the development and commercialization of lecanemab, which is approved in 53 countries. The company's ongoing clinical studies aim to further enhance understanding and treatment of Alzheimer's disease, with a focus on early intervention and patient-centered care.